Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.61 |
| ▸ | CDC25A | P30304 | 5/20 | 0.56 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9664069 | 1.00 | CYP2D6 (0.62) | CYP2D6CYP2C19INPP5DCDC25ACDC25B | |
| SCHEMBL15346210 | 0.91 | CYP2D6 (0.62) | CYP2D6CYP2C19INPP5DCDC25ACDC25B | |
| SCHEMBL19064993 | 0.91 | GPBAR1 (0.53) | CYP2D6CYP2C19INPP5DCDC25AMEN1 | |
| SCHEMBL9580113 | 0.89 | GPBAR1 (0.51) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL28057976 | 0.89 | CYP2D6 (0.62) | CYP2D6CYP2C19INPP5DCDC25ACDC25B | |
| SCHEMBL1618569 | 0.89 | GPBAR1 (0.54) | CYP2D6CYP2C19INPP5DMEN1LMNA | |
| SCHEMBL19064920 | 0.89 | GPBAR1 (0.54) | CYP2D6CYP2C19INPP5DMEN1LMNA | |
| SCHEMBL28959940 | 0.88 | CYP2D6 (0.58) | CYP2D6CYP2C19INPP5DCDC25ACDC25B | |
| SCHEMBL4729443 | 0.87 | CYP2D6 (0.65) | CYP2D6CYP2C19INPP5DCDC25ACDC25B | |
| SCHEMBL1492159 | 0.87 | CYP2D6 (0.62) | CYP2D6CYP2C19INPP5DCDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185496-B2 | Bioerodible implant for long-term drug delivery and associated methods of manufacture and use | GESEA BIOSCIENCES, INC. (US) | 2021-11-30 | — | — | US | claimed |
| CN-106535876-B | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications | 埃克西奎雷股份有限公司 | 2020-09-11 | — | — | CN | claimed |
| US-20020183283-A1 | Meiosis regulating compounds | FAARUP PETER (DK) | 2002-12-05 | — | — | US | claimed |
| US-20010003782-A1 | Meiosis regulating compounds | NOVA NORDISK A/S (DK) | 2001-06-14 | — | — | US | claimed |
| US-11833244-B2 | Bioerodible implant for long-term drug delivery and associated methods of manufacture and use | Gesea Biosciences Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116497082-B | Method for synthesizing 3 alpha, 7 alpha, 24R-trihydroxy cholesterol by chemical-enzymatic method | 华南理工大学 | 2023-09-29 | — | — | CN | disclosed |
| EP-3368024-B1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES INC (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116497082-A | Method for synthesizing 3 alpha, 7 alpha, 24R-trihydroxy cholesterol by chemical-enzymatic method | 华南理工大学 | 2023-07-28 | — | — | CN | disclosed |
| US-20220249365-A1 | BIOERODIBLE IMPLANT FOR LONG-TERM DRUG DELIVERY AND ASSOCIATED METHODS OF MANUFACTURE AND USE | Gesea Biosciences Inc. (US) | 2022-08-11 | — | — | US | disclosed |
| CN-114315947-A | Novel method for synthesizing cholesterol and 25-hydroxycholesterol by using 22-sterol as raw material | 上海敏韬医药科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220054429-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11185496-B2 | Bioerodible implant for long-term drug delivery and associated methods of manufacture and use | GESEA BIOSCIENCES, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20180085305-A1 | BIOERODIBLE IMPLANT FOR LONG-TERM DRUG DELIVERY AND ASSOCIATED METHODS OF MANUFACTURE AND USE | Gesea Biosciences Inc. (US) | 2018-03-29 | — | — | US | disclosed |
| WO-2017072773-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | NATHAN ILANA (IL) | 2017-05-04 | — | — | WO | disclosed |
| CN-106537145-A | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-20010003782-A1 | Meiosis regulating compounds | NOVA NORDISK A/S (DK) | 2001-06-14 | — | — | US | disclosed |
| EP-0203968-B1 | METHOD FOR IMMUNOANALYSIS OF CHOLESTEROL EPOXIDES | SCHAFFNER, Carl P. (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0203968-A4 | METHOD FOR IMMUNOANALYSIS OF CHOLESTEROL EPOXIDES. | SCHAFFNER CARL P | 1989-06-14 | — | — | EP | disclosed |
| EP-0203968-A1 | METHOD FOR IMMUNOANALYSIS OF CHOLESTEROL EPOXIDES. | SCHAFFNER CARL P | 1986-12-10 | — | — | EP | disclosed |
| WO-1986003299-A1 | METHOD FOR IMMUNOANALYSIS OF CHOLESTEROL EPOXIDES | SCHAFFNER CARL P | 1986-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183283-A1 | Meiosis regulating compounds | SREBF2, SREBF1, TRIP13 | CYP2D6 3846/4885CYP2C19 4130/4885INPP5D 1443/4885 |
| US-20010003782-A1 | Meiosis regulating compounds | SREBF2, SREBF1, TRIP13 | CYP2D6 3846/4885CYP2C19 4130/4885INPP5D 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.